Jonny Karunia Fajar1, Malik Sallam2,3,4, Gatot Soegiarto5, Yani Jane Sugiri6, Muhammad Anshory7, Laksmi Wulandari8, Stephanie Astrid Puspitasari Kosasih9, Muhammad Ilmawan10, Kusnaeni Kusnaeni11, Muhammad Fikri11, Frilianty Putri12, Baitul Hamdi13, Izza Dinalhaque Pranatasari14, Lily Aina15, Lailatul Maghfiroh16, Fernanda Septi Ikhriandanti17, Wa Ode Endiaverni18, Krisna Wahyu Nugraha18, Ory Wiranudirja18, Sally Edinov19, Ujang Hamdani18, Lathifatul Rosyidah18, Hanny Lubaba18, Rinto Ariwibowo18, Riska Andistyani18, Ria Fitriani20, Miftahul Hasanah21, Fardha Ad Durrun Nafis21, Fredo Tamara1, Fitri Olga Latamu1, Hendrix Indra Kusuma22,23,24, Ali A Rabaan25,26,27, Saad Alhumaid28, Abbas Al Mutair29,30,31,32, Mohammed Garout33, Muhammad A Halwani34, Mubarak Alfaresi35,36, Reyouf Al Azmi37, Nada A Alasiri38, Abeer N Alshukairi26,39, Kuldeep Dhama40, Harapan Harapan22,41,42. 1. Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang 65145, Indonesia. 2. Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan. 3. Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital, Amman 11942, Jordan. 4. Department of Translational Medicine, Faculty of Medicine, Lund University, 22184 Malmö, Sweden. 5. Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60286, Indonesia. 6. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang 65145, Indonesia. 7. Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang 65145, Indonesia. 8. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60286, Indonesia. 9. Faculty of Medicine, Universitas Brawijaya, Malang 65145, Indonesia. 10. Department of Urology, Faculty of Medicine, Universitas Brawijaya, Malang 65145, Indonesia. 11. Faculty of Matematics and Sciences, Institut Pertanian Bogor, Bogor 16680, Indonesia. 12. School of Veterinary Medicine and Biomedicine, Institut Pertanian Bogor, Bogor 16680, Indonesia. 13. Faculty of Economy and Business, Universitas Airlangga, Surabaya 60286, Indonesia. 14. Faculty of Public Health, Universitas Airlangga, Surabaya 60286, Indonesia. 15. Faculty of Pharmacy, Universitas Airlangga, Surabaya 60286, Indonesia. 16. Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya 60286, Indonesia. 17. Faculty of Medicine, Universitas Airlangga, Surabaya 60286, Indonesia. 18. Faculty of Economy and Business, Universitas Brawijaya, Malang 65145, Indonesia. 19. Faculty of Economics and Business, Riau University, Pekanbaru 28293, Indonesia. 20. Faculty of Administrative Science, Universitas Brawijaya, Malang 65145, Indonesia. 21. Faculty of Animal Science, Universitas Brawijaya, Malang 65145, Indonesia. 22. Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia. 23. Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Darussalam, Banda Aceh 23111, Indonesia. 24. Faculty of Tarbiyah and Teacher Training, Universitas Islam Negeri Ar-Raniry, Banda Aceh 23111, Indonesia. 25. Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia. 26. College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. 27. Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan. 28. Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa 31982, Saudi Arabia. 29. Research Center, Almoosa Specialist Hospital, Al Mubarrazs 36342, Saudi Arabia. 30. College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia. 31. School of Nursing, Wollongong University, Wollongong, NSW 2522, Australia. 32. Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran 33048, Saudi Arabia. 33. Department of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia. 34. Department of Medical Microbiology, Faculty of Medicine, Al Baha University, Al Baha 4781, Saudi Arabia. 35. Department of Pathology and Laboratory Medicine, Sheikh Khalifa General Hospital, Umm Al Quwain 499, United Arab Emirates. 36. Department of Pathology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai 505055, United Arab Emirates. 37. Infection Prevention and Control, Eastern Health Cluster, Dammam 32253, Saudi Arabia. 38. Scientific Advisory Council, InsanCare Group for Scientific Studies and Specialized Business Solutions, Riyadh 13313, Saudi Arabia. 39. Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah 12713, Saudi Arabia. 40. Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India. 41. Tropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia. 42. Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia.
Abstract
Countries worldwide have deployed mass COVID-19 vaccination drives, but there are people who are hesitant to receive the vaccine. Studies assessing the factors associated with COVID-19 vaccination hesitancy are inconclusive. This study aimed to assess the global prevalence of COVID-19 vaccination hesitancy and determine the potential factors associated with such hesitancy. We performed an organized search for relevant articles in PubMed, Scopus, and Web of Science. Extraction of the required information was performed for each study. A single-arm meta-analysis was performed to determine the global prevalence of COVID-19 vaccination hesitancy; the potential factors related to vaccine hesitancy were analyzed using a Z-test. A total of 56 articles were included in our analysis. We found that the global prevalence of COVID-19 vaccination hesitancy was 25%. Being a woman, being a 50-year-old or younger, being single, being unemployed, living in a household with five or more individuals, having an educational attainment lower than an undergraduate degree, having a non-healthcare-related job and considering COVID-19 vaccines to be unsafe were associated with a higher risk of vaccination hesitancy. In contrast, living with children at home, maintaining physical distancing norms, having ever tested for COVID-19, and having a history of influenza vaccination in the past few years were associated with a lower risk of hesitancy to COVID-19 vaccination. Our study provides valuable information on COVID-19 vaccination hesitancy, and we recommend special interventions in the sub-populations with increased risk to reduce COVID-19 vaccine hesitancy.
Countries worldwide have deployed mass COVID-19 vaccination drives, but there are people who are hesitant to receive the vaccine. Studies assessing the factors associated with COVID-19 vaccination hesitancy are inconclusive. This study aimed to assess the global prevalence of COVID-19 vaccination hesitancy and determine the potential factors associated with such hesitancy. We performed an organized search for relevant articles in PubMed, Scopus, and Web of Science. Extraction of the required information was performed for each study. A single-arm meta-analysis was performed to determine the global prevalence of COVID-19 vaccination hesitancy; the potential factors related to vaccine hesitancy were analyzed using a Z-test. A total of 56 articles were included in our analysis. We found that the global prevalence of COVID-19 vaccination hesitancy was 25%. Being a woman, being a 50-year-old or younger, being single, being unemployed, living in a household with five or more individuals, having an educational attainment lower than an undergraduate degree, having a non-healthcare-related job and considering COVID-19 vaccines to be unsafe were associated with a higher risk of vaccination hesitancy. In contrast, living with children at home, maintaining physical distancing norms, having ever tested for COVID-19, and having a history of influenza vaccination in the past few years were associated with a lower risk of hesitancy to COVID-19 vaccination. Our study provides valuable information on COVID-19 vaccination hesitancy, and we recommend special interventions in the sub-populations with increased risk to reduce COVID-19 vaccine hesitancy.
Coronavirus disease 2019 (COVID-19) vaccination has been progressing globally since the beginning of 2021. Several types of vaccines, including inactivated, vector-based, messenger ribonucleic acid (mRNA), and protein subunit vaccines, are being administered to recipients [1]. Since the vaccines became available, there have been expectations of the COVID-19 pandemic ending, considering that previous vaccination programs have been effective in managing several infectious diseases such as rubella, mumps, measles, and polio. These vaccination programs have been proven to improve global health and the economy [2,3]. However, the probability of failure of any vaccination program should be assessed. A study reported that the barriers to effective vaccination programs include inconvenient and limited clinic hours for immunization, inadequate access to healthcare, high vaccine administration fees, and vaccine hesitancy [4]. Of these factors, vaccine hesitancy is considered one of the most critical [5]. Individuals who are hesitant to be immunized have a tendency to spread incorrect information about vaccination, which may influence people close to them to reject vaccines as well [6].Vaccine hesitancy is commonly observed in the case of new vaccines or vaccine candidates [7,8]. This phenomenon was reported in the case of malaria [9], dengue [10], and Ebola [11]. The factors contributing to vaccine hesitancy are complex and may include a lack of awareness regarding disease prevention and socioeconomic status [12,13]. This phenomenon poses a dilemma to vaccine coverage. Moreover, governments—as the highest regulatory authority of any nation—seemingly do not provide special interventions to reduce hesitancy toward vaccination programs. It is observed in the guidelines on COVID-19 vaccination, that the primary recommendation only focused on dose allocation, outreach, delivery, and monitoring; there was no information on how to reduce COVID-19 vaccination hesitancy [14].Regarding COVID-19 vaccination, several studies have been conducted to assess the prevalence of COVID-19 vaccine hesitancy and its associated predictors [7,8,15]. However, the findings were inconclusive with variability regarding the correlation between COVID-19 vaccine acceptance and the following: sociodemographic factors, vaccine confidence and trust regarding vaccine safety, complacency towards the disease, conspiracy beliefs towards COVID-19 vaccination and willingness to pay for the vaccine [7,16,17,18,19,20,21]. Therefore, a meta-analysis is necessary to determine the potential factors influencing COVID-19 vaccination hesitancy.
2. Materials and Methods
2.1. Study Design
During the period May–June 2022, we conducted a meta-analysis that followed the protocols of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) [22,23]. In line with the purpose of our study, we first performed an organized search of PubMed, Scopus, and Web of Science and, subsequently, collected the required information to calculate the global prevalence of vaccine hesitancy and effect estimates of the potential influencing factors. The PRISMA checklist for this review is provided in (Supplementary Materials). Additionally, data used in this review are available in Figshare (https://doi.org/10.6084/m9.figshare.20055539.v3, accessed on 6 December 2022) [23].
2.2. Eligibility Criteria
We determined the eligibility criteria before conducting the organized search. An article was included in the analysis if the following inclusion criteria were met: (1) whether it assessed the prevalence of COVID-19 vaccination hesitancy or (2) identified potential factors influencing COVID-19 vaccination hesitancy. Reviews, commentaries, letters to the editor, grey literature, and double publications were excluded.
2.3. Search Strategy and Data Extraction
As of 25 May 2022, we performed an organized search of PubMed, Scopus, and Web of Science. Prior to the search for the main outcomes, the potential factors associated with COVID-19 vaccination hesitancy were determined. We used keywords from the following medical subject headings: “vaccine”, “vaccination”, or “immunization”; “COVID-19” or “coronavirus disease 2019”; “hesitancy” or “acceptance”. We limited the organized search to the English language. If we found any duplication, we included the studies with larger sample sizes. Furthermore, we also conducted an organized search of the reference lists of the relevant articles to obtain additional papers. Thereupon, the following information was collected from the selected articles: (1) first author name, (2) year of publication, (3) study design, (4) study period, (5) Newcastle–Ottawa scale (NOS), (6) the prevalence of COVID-19 vaccination hesitancy, and (7) event rate of potential factors associated with COVID-19 vaccination hesitancy. Two independent teams, led by JKF and SAPK, conducted the article search and data extraction. Prior to the systematic search, the kappa statistic was used to measure the agreement between the two investigators. If the kappa statistic was greater than the p-value, agreement was established.
2.4. Assessment of the Methodological Quality
All potential articles for inclusion in the study were assessed for quality using NOS [24]. The quality was considered high, moderate, or low if the score was 7–9, 4–6, or 0–3, respectively. Low-quality articles were excluded from the analysis. Using a pilot form, the two independent teams, led by JKF and SAPK, conducted the NOS assessment, and any discrepancies were resolved through discussion.
2.5. Outcome Measures
The major outcomes were global prevalence and potential influencing factors of COVID-19 vaccination hesitancy. To identify the potential factors associated with vaccine hesitancy, we performed an initial organized search in PubMed, Scopus, and Web of Science. We identified the following potential factors: age group, gender, marital status, educational attainment, religion, employment status, healthcare-related job, socioeconomic status, urbanity, presence of children and elderly people at home, household size, and presence of family members with a medical background. Additionally, wearing masks, hand hygiene, compliance with physical distancing norms, smoking, history of chronic disease, personal history of COVID-19 diagnosis, COVID-19 diagnosis of a family member/friend, hospitalization due to COVID-19 among people in the same social circle, death owing to COVID-19 among people in the same social circle, safety conceptions about COVID-19 vaccines, and history of influenza vaccination in the past few years were also factors of interest.
2.6. Statistical Analysis
Before calculating the global prevalence of COVID-19 vaccination hesitancy and effect estimates of potential predictors of such hesitancy, we conducted an analysis of potential publication bias and heterogeneity among the studies. We analyzed the risk of publication bias using the Egger’s test, with a p-value of <0.05 suggesting the existence of publication bias. Furthermore, we performed an analysis of heterogeneity among studies using the Q test, with a p-value of <0.10 indicating heterogeneity; thus, a random effects model was applied for data analysis—in cases where there was no heterogeneity, a fixed-effects model was used. A single-arm meta-analysis was performed using the dichotomous covariate method to calculate the event rate from each study to discern the global prevalence of COVID-19 vaccination hesitancy. The effect estimate was presented as the event rate. The analysis was performed using the R package (RStudio version 4.1.1, R Studio, Boston, MA, USA). The effect estimates of potential factors associated with COVID-19 vaccination hesitancy were outlined in a forest plot as a pooled odds ratio and 95% confidence interval (OR, 95% CI).
3. Results
3.1. Selection of Studies
We retrieved 4299 potential papers from the databases mentioned and 18 from the reference lists of related articles. Of these, 23 papers were excluded owing to duplication and 4219 papers with irrelevant subjects. Thus, 75 articles were included in the full-text review. Subsequently, six reviews and thirteen articles were excluded because of insufficient data. Eventually, a total of 56 articles were included in the final analysis to calculate the global prevalence and potential influencing factors in COVID-19 vaccination hesitancy [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79]. The plotting of article selection in our study is presented in (Figure 1), and the characteristics of the included articles are listed in (Table 1).
Figure 1
A flowchart of article selection in this review.
Table 1
Baseline characteristics of articles included in our analysis [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
Author and Year
Country
Sample Size
Study Period
Population
Funding
NOS 1
Aemro et al., 2021 [25]
Ethiopia
418
May–June 2021
Healthcare workers
No funding
5
Ali et al., 2021 [26]
Bangladesh
1134
January 2021
General population
No funding
6
Barry et al., 2021 [27]
Saudi Arabia
1512
November 2020
Healthcare workers
No funding
6
Bell et al., 2020 [28]
England
1252
April–May 2020
General population
London School of Hygiene and Tropical Medicine
6
Chen et al., 2021 [29]
China
2531
January 2021
General population
NA
7
Chudasama et al., 2022 [30]
Multinational
275
April–July 2021
Healthcare workers
NA
6
Detoc et al., 2020 [31]
France
3259
March–April 2020
General population
NA
5
Dong et al., 2020 [32]
China
1236
June–July 2020
General population
Chinese University of Hong Kong
6
Dror et al., 2020 [33]
Israel
1661
2020–2022
Healthcare workers
NA
5
Faasse et al., 2020 [34]
Australia
2232
March 2020
General population
UNSW Science Goldstar (2020)
5
Fisher et al., 2020 [35]
US
991
April 2020
General population
Agency for Healthcare Research and Quality
7
Goodwin et al., 2022 [36]
Multinational
3059
December 2020–January 2021
General population
Ariel University, JSPS KAKENSHI, Hungaria National Excellence Program
6
Habib et al., 2022 [37]
Saudi Arabia
1445
August–October 2021
Students
King Saud University
7
Bou Hamdan et al., 2021 [38]
Lebanon
758
May–June 2021
Students
No funding
7
Harapan et al., 2020 [39]
Indonesia
1359
March–April 2020
General population
No funding
6
Horiuchi et al., 2021 [40]
Japan
1200
May–June 2021
General population
No funding
7
Hossain et al., 2021 [41]
Bangladesh
1497
February 2021
General population
No funding
6
Huang et al., 2022 [42]
China
4227
January–March 2021
General population
National Health Commission of the People’s Republic of China
7
Ikiisik et al., 2021 [43]
Turkey
384
December 2020
General population
NA
7
Jabessa et al., 2022 [44]
Ethiopia
350
August–September 2021
General population
No funding
6
Jain et al., 2021 [45]
India
1068
February–March 2021
Students
No funding
6
Kelekar et al., 2021 [46]
US
408
September–December 2020
Students
NA
6
Khubchandani et al., 2021 [47]
US
1878
June 2020
General population
No funding
8
Koh et al., 2022 [48]
Singapore
528
May–June 2021
Healthcare workers
No funding
6
Kumar et al., 2021 [49]
Qatar
1414
October–November 2020
Healthcare workers
Qatar National Library
5
Lazarus et al., 2020 [50]
Multinational
13,426
June 2020
General population
City University of New York
6
Lee et al., 2022 [51]
South Korea
1016
January 2021
General population
No funding
6
Li et al., 2022 [52]
China
721
June 2021
Students
Xuzhou Medical University
7
Liddell et al., 2021 [53]
Australia
437
June 2021
General population
UNSW Sydney/Australian Red Cross
6
Lucia et al., 2021 [54]
US
167
NA
Students
No funding
5
Malik et al., 2020 [55]
US
672
May 2020
General population
Yale Institute for Global Health
8
Marzo et al., 2022 [56]
Multinational
5260
February–May 2021
General population
No funding
7
Mascarenhas et al., 2021 [57]
US
245
2020
Students
No funding
6
Mohammed et al., 2021 [58]
Ethiopia
614
March–July 2021
Healthcare workers
No funding
7
Mose et al., 2022 [59]
Ethiopia
420
March 2021
Students
No funding
6
Nery et al., 2022 [60]
Brazil
2537
November 2020–January 2021
General population
Brazilian Ministry of Health
8
Neumann-Böhme et al., 2020 [61]
Multinational
7664
April 2020
General population
European Union’s Horizon 2020 research and innovation programme
6
Ousseine et al., 2022 [62]
France
15,427
February–April 2021
General population
National Agency for Research on AIDS and Viral Hepatitis (ANRS)
6
Patwary et al., 2021 [19]
Bangladesh
543
July–August 2021
General population
No funding
6
Qunaibi et al., 2021 [63]
Multinational
36,220
January 2021
General population
No funding
7
Raja et al., 2022 [64]
Sudan
217
June–July 2021
Students
No funding
5
Reiter et al., 2020 [65]
US
2006
May 2020
General population
National Center for Advancing Translational Sciences
7
Rodríguez-Blanco et al., 2021 [66]
Spain
2494
November–December 2020
General population
No funding
6
Saied et al., 2021 [67]
Egypt
2133
January 2021
Students
NA
7
Salali et al., 2020 [68]
Multinational
5024
May 2020
General population
No funding
6
Schwarzinger et al., 2021 [69]
France
1942
July 2020
General population
French Public Health Agency
7
Shah et al., 2021 [70]
India
274
February 2021
Students
NA
7
Singh et al., 2021 [71]
Hong Kong
245
May 2021
General population
Tung Foundation
7
Tao et al., 2021 [72]
China
1392
November 2020
General population
National Key Research and Development Project of China
7
Tlale et al., 2022 [73]
Botswana
4952
February 2021
General population
No funding
6
Wang et al., 2020 [74]
Hong Kong
806
February–March 2020
Healthcare workers
No funding
6
Ward et al., 2020 [75]
France
5018
April 2020
General population
Agence Nationale de la Recheche and the CNRS
8
Wong et al., 2020 [76]
Malaysia
1159
April 2020
General population
Ministry of Education Malaysia
8
Wu et al., 2021 [77]
China
29,925
August 2021
General population
National Social Science Fund of China
7
Xu et al., 2021 [78]
China
5247
January 2021
Healthcare workers
Health Commission of Chongqing municipal, China
6
Yassin et al., 2022 [79]
Sudan
365
April 2021
Healthcare workers
NA
6
1 NOS: Newcastle–Ottawa scale; all selected studies were based on a cross-sectional design.
3.2. Global Prevalence of COVID-19 Vaccination Hesitancy
To calculate the global prevalence of COVID-19 vaccination hesitancy, we included a total of 56 articles. Data analysis using the random effects model revealed that the global prevalence was 25% (event rate: 0.25; 95% CI: 0.19, 0.32; p Egger’s: 1.2710; p heterogeneity: <0.0001; p < 0.0001). The global prevalence of COVID-19 vaccination hesitancy is presented in (Figure 2A). In sub-group analysis, we found that the prevalence of COVID-19 vaccination hesitancy in the general population (Figure 2B), healthcare workers (Figure 2C), and students (Figure 2D) was 25%, 26%, and 25%, respectively.
Figure 2
The global prevalence of hesitancy to COVID-19 vaccination (event rate: 0.25; 95% CI: 0.20, 0.32; p Egger: 1.2580; p heterogeneity: <0.0001; p: <0.0001) (A). The prevalence of hesitancy to COVID-19 vaccination among general population (event rate: 0.25; 95% CI: 0.18, 0.34; p Egger: 1.3090; p heterogeneity: <0.0001; p: <0.0001) (B). The prevalence of hesitancy to COVID-19 vaccination among healthcare workers (event rate: 0.26; 95% CI: 0.18, 0.37; p Egger: 0.7670; p heterogeneity: <0.0001; p: <0.0001) (C). The prevalence of hesitancy to COVID-19 vaccination among students (event rate: 0.25; 95% CI: 0.14, 0.40; p Egger: 1.2090; p heterogeneity: <0.0001; p: 0.0030) (D). The studies included are provided in the reference list [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
3.3. Potential Factors Associated with COVID-19 Vaccination Hesitancy
The potential factors associated with COVID-19 vaccination hesitancy are summarized in (Table 2) and presented in (Figure 3, Figure 4, Figure 5 and Figure 6). Our analysis revealed that out of 25 factors, 12 of them were associated with COVID-19 vaccine hesitancy. The following factors were associated with a higher risk of vaccination hesitancy: being a woman (compared to man) (Figure 3A), being ≤50 years old (compared to those older than 50 years (Figure 3B), being single (compared to married individuals) (Figure 3C), being unemployed (compared to employed) (Figure 4A), living in a household with five or more individuals (compared to living in smaller households) (Figure 4B), having an educational attainment lower than an undergraduate degree (compared to those with an undergraduate degree or higher) (Figure 5A), having a non-healthcare-related job (compared to having a healthcare-related job) (Figure 5B), and considering COVID-19 vaccines to be unsafe (compared to those who consider COVID-19 vaccines to be safe) (Figure 5C).
Table 2
The potential factors associated with the hesitancy to COVID-19 vaccination.
Covariates
Hesitancy/Total (n [%])
NS
p Egger
p Het
OR
95% CI
p
Age group (years)
≤30
6568/14,356 [45.8]
16
0.2320
<0.0001
1.14
0.98–1.32
0.0870
31–40
5097/11,335 [45.0]
16
0.2360
<0.0001
1.09
0.94–1.26
0.2630
41–50
3034/6536 [46.4]
15
0.2730
<0.0001
0.88
0.74–1.06
0.1760
>50
2034/4677 [43.5]
13
0.2980
<0.0001
0.79
0.64–0.98
0.0290
Sex
Male
8934/22,362 [40.0]
31
0.2840
<0.0001
0.76
0.67–0.85
<0.0001
Female
11,170/28,707 [38.9]
31
0.2840
<0.0001
1.32
1.17–1.49
<0.0001
Marital status
Married
6888/20,496 [33.6]
17
0.1950
<0.0001
0.84
0.75–0.95
0.0040
Single
7173/18,764 [38.2]
17
0.1950
<0.0001
1.19
1.06–1.34
0.0040
Educational attainment
<BSC
12,130/22,950 [52.9]
22
0.5260
<0.0001
1.30
1.03–1.65
0.0300
≥BSC
17,532/41,182 [42.6]
22
0.5260
<0.0001
0.77
0.61–0.97
0.0300
Religion
Christian
1053/2124 [49.6]
5
<0.0001
0.4380
1.17
1.01–1.35
0.0340
Muslim
1265/3961 [31.9]
6
0.5110
<0.0001
1.39
0.85–2.26
0.1860
Hindu
16/129 [12.4]
2
1.5700
0.0710
0.28
0.02–3.40
0.3150
Employment
Not working
1704/4455 [38.2]
10
0.1790
0.0090
1.20
1.02–1.42
0.0300
Working
5883/16,413 [35.8]
10
0.1790
0.0090
0.83
0.71–0.98
0.0300
Healthcare-related job
2886/8313 [34.7]
10
0.3340
<0.0001
0.68
0.52–0.89
0.0040
Socioeconomic status
Low income
1320/2939 [44.9]
7
0.4840
<0.0001
1.31
0.88–1.94
0.1790
Middle income
1217/3220 [37.8]
7
1.2050
<0.0001
0.61
0.25–1.52
0.2900
High income
1427/2515 [56.7]
7
1.2860
<0.0001
1.28
0.49–3.38
0.6140
Urbanicity
Urban
9192/28,583 [32.2]
15
0.4500
<0.0001
0.92
0.72–1.18
0.5070
Rural
3128/8338 [37.5]
15
0.4500
<0.0001
1.09
0.85–1.39
0.5070
Children at home
1207/4595 [26.3]
8
1.4040
<0.0001
0.37
0.14–0.99
0.0490
Aged people at home
456/1542 [29.6]
5
0.2760
0.0140
1.07
0.78–1.45
0.6920
Household number (n)
≤2
930/3192 [29.1]
5
0.3900
<0.0001
0.94
0.64–1.36
0.7270
3–4
564/2067 [27.3]
5
0.2290
0.0110
0.89
0.69–1.14
0.3510
≥5
278/712 [39.0]
4
0.1680
0.1620
1.36
1.13–1.63
0.0010
Family members with medical backgrounds
464/1382 [33.6]
2
0.0410
0.3170
0.92
0.78–1.07
0.2770
Wearing masks all the time
1523/6606 [23.1]
6
0.5570
<0.0001
0.61
0.36–1.05
0.0720
Constantly washing hands
1209/4974 [24.3]
4
0.8900
<0.0001
0.45
0.18–1.16
0.0980
Keep physical distancing
213/745 [28.6]
3
0.8370
0.0010
0.23
0.08–0.65
0.0050
Smoker
665/2236 [29.7]
5
0.0590
0.3360
1.13
0.99–1.29
0.0610
History of chronic disease(s)
3828/8197 [46.7]
17
0.1840
<0.0001
0.91
0.80–1.03
0.1420
Ever tested for COVID-19
670/4430 [15.1]
6
0.4340
<0.0001
0.46
0.31–0.68
<0.0001
Personal history of COVID-19 diagnosis
4114/7733 [53.2]
15
0.6090
<0.0001
0.94
0.66–1.33
0.7150
Family member/friend ever diagnosed with COVID-19
1192/3759 [31.7]
7
0.2960
<0.0001
0.83
0.63–1.09
0.1730
Hospitalization due to COVID-19 among people in the same social circle
69/621 [11.1]
2
<0.0001
0.9770
0.57
0.37–0.88
0.0110
Death due to COVID-19 among people in the same social circle
63/537 [11.7]
3
<0.0001
0.9450
0.73
0.49–1.08
0.1160
COVID-19 vaccines are not safe
628/1595 [39.4]
6
0.7000
<0.0001
2.24
1.21–4.14
0.0100
Influenza vaccination in the past few years
3481/10,687 [32.6]
11
0.3460
<0.0001
0.46
0.36–0.58
<0.0001
OR: odds ratio; CI: confidence interval; NS: number of studies; p Het: p heterogeneity; BSC: Bachelor of Science.
Figure 3
Female was associated with increased risk of hesitancy to COVID-19 vaccination compared to male (OR: 1.32; 95% CI: 1.17, 1.49; p Egger: 0.2840; p heterogeneity: <0.0001; p: <0.0001) (A). Individuals with age > 50 years was associated with lower risk of hesitancy to COVID-19 vaccination compared to individuals with age ≤ 50 years (OR: 0.79; 95% CI: 0.64, 0.98; p Egger: 0.2980; p Het: <0.0001; p: 0.0290) (B). Single individuals had higher risk of hesitancy to COVID-19 vaccination than married individuals (OR: 1.19; 95% CI: 1.06, 1.34; p Egger: 0.1950; p heterogeneity: <0.0001; p: 0.0040) (C). The studies included are provided in the reference list [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
Figure 4
Unemployed individuals were associated with increased risk of hesitancy to COVID-19 vaccination compared to working individuals (OR: 1.20; 95% CI: 1.02, 1.42; p Egger: 0.1790; p heterogeneity: 0.0090; p: 0.0300) (A); individuals with household number ≥ 5 individuals had higher risk of hesitancy to COVID-19 vaccination (OR: 1.36; 95% CI: 1.13, 1.63; p Egger: 0.1680; p heterogeneity: 0.1620; p: 0.0010) (B). The studies included are provided in the reference list [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
Figure 5
Individuals with the education levels < BSC had higher risk of hesitancy to COVID-19 vaccination than ≥ BSC (OR: 1.30; 95% CI: 1.03, 1.65; p Egger: 0.5260; p heterogeneity: <0.0001; p: 0.0300) (A); individuals having the healthcare-related job had lower risk of hesitancy to COVID-19 vaccination (OR: 0.68; 95% CI: 0.52, 0.89; p Egger: 0.3340; p heterogeneity: <0.0001; p: 0.0040) (B); Individuals considering that COVID-19 vaccines are not safe had higher risk of hesitancy to COVID-19 vaccination (OR: 2.24; 95% CI: 1.21, 4.14; p Egger: 0.7000; p heterogeneity: <0.0001; p: 0.0100) (C). The studies included are provided in the reference list [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
Figure 6
Individuals living with children in the home had lower risk of hesitancy to COVID-19 vaccination (OR: 0.37; 95% CI: 0.14, 0.99; p Egger: 1.4040; p heterogeneity: <0.0001; p: 0.0490) (A); individuals keeping physical distancing had lower risk of hesitancy to COVID-19 vaccination (OR: 0.23; 95% CI: 0.08, 0.65; p Egger: 0.8370; p heterogeneity: 0.0010; p: 0.0050 (B); individuals with history of COVID-19 test were associated with lower risk of hesitancy to COVID-19 vaccination (OR: 0.46; 95% CI: 0.31, 0.68; p Egger: 0.4340; p heterogeneity: <0.0001; p: <0.0001) (C); individuals with history of influenza vaccination in the past few years had lower risk of hesitancy to COVID-19 vaccination (OR: 0.46; 95% CI: 0.36, 0.58; p Egger: 0.3460; p heterogeneity: <0.0001; p: <0.0001) (D). The studies included are provided in the reference list [19,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
In contrast, living with children at home (compared to having no child at home) (Figure 6A), maintaining physical distancing norms (compared to not following such norms) (Figure 6B), having ever tested for COVID-19 (compared to having never tested for COVID-19) (Figure 6C), and having a history of influenza vaccination in the past few years (compared to not having been vaccinated for influenza in the past few years) (Figure 6D) were associated with a lower risk of hesitancy to COVID-19 vaccination.
3.4. Source of Heterogeneity and Potential Publication Bias
Heterogeneity was not found for six variables (Christian religion, household size ≥ 5 individuals, family members with a medical background, smoking, hospitalization due to COVID-19 among people in the same social circle, and death owing to COVID-19 among people in the same social circle). Therefore, we used a fixed-effects model. Conversely, other variables were assessed using a random effects model. The Egger’s test was used to assess potential bias among the studies. Our pooled analyses revealed a risk of publication bias for the following covariates: the Christian religion, family members with a medical background, hospitalization due to COVID-19 among people in the same social circle, and death owing to COVID-19 among people in the same social circle (Table 2).
4. Discussion
Our study estimated the global prevalence of COVID-19 vaccination hesitancy at 25%. The current findings are consistent with those of previous meta-analyses, which estimated the prevalence of vaccine hesitancy in the general population at 26–42% [15,80,81,82,83]. In special populations, previous meta-analyses revealed that the hesitancy for COVID-19 vaccination was estimated at 24%, 27%, and 26% in multiple sclerosis patients, older people, and healthcare students, respectively [84,85,86]. Furthermore, hesitancy to receive a COVID-19 booster was reported at 21% in the general population [87]. Moreover, high rates of COVID-19 vaccine hesitancy were reported among the ethnic minorities in the UK [88]. Our estimate was in the range of extant literature. However, our study had a larger sample size, which might have provided a more accurate calculation. Moreover, in sub-group analysis, we also identified that the prevalence of COVID-19 vaccination hesitancy was 25%, 26%, and 25% in the general population, healthcare workers, and students, respectively. This study also identified the potential predictors of COVID-19 vaccine hesitancy, thereby providing more comprehensive evidence on this phenomenon.The current study noted that the potential factors associated with COVID-19 vaccination hesitancy can be contextualized in terms of awareness, knowledge, and socioeconomic status. In the context of awareness of COVID-19 vaccination, we found that older people (>50 years), those living with children at home, individuals who have ever tested for COVID-19, and those with a history of influenza vaccination had a lower risk of COVID-19 vaccination hesitancy. In contrast, several factors, such as single marital status and unemployment, were associated with an increased risk of hesitancy toward COVID-19 vaccination.The precise underlying factors contributing to COVID-19 vaccination hesitancy could not be defined clearly. However, some presumptions may explain these findings. Older individuals are more likely to suffer from one or more chronic diseases compared to younger people. In our previous investigation, we found that advanced age and comorbidity were associated with an increased risk of severity in COVID-19 patients [89]. Therefore, the possibility of an increased risk of severe COVID-19 might influence the awareness of such individuals and contribute to a lower risk of COVID-19 vaccination hesitancy in this group due to low levels of complacency [90].Similarly, individuals living with children at home might be afraid of transmitting the virus to their children should they be infected with COVID-19. Therefore, it is reasonable that this group is less hesitant to receive COVID-19 vaccination. Interestingly, a similar impact was not observed in individuals living with elderly people at home. This ironic finding is supported by previous studies, which found that living with children was a crucial determinant of health-related behavior [91], whereas this was not the case for individuals living with elderly people [92].Furthermore, individuals who have ever tested for COVID-19 and had a history of influenza vaccination might have had good practice in disease prevention. Disease screening and vaccination history have been shown to affect health behavior, which can possibly explain why this group is less averse to COVID-19 vaccination. Moreover, married individuals might engage in protective behavior toward their spouse; couples have mutual concern and might have a better life expectancy than single individuals. A previous study found that married individuals had better health behavior and a lower risk of mortality than single individuals [93]. Thus, single individuals might be more averse than married individuals to COVID-19 vaccination. This reason, in the context of poor health behavior, might also explain vaccine hesitancy in unemployed individuals.Our study also found that individuals with lower educational levels and those who consider COVID-19 vaccines to be unsafe had a higher risk of COVID-19 vaccination hesitancy. In contrast, individuals with healthcare-related jobs had a lower risk of COVID-19 vaccination hesitancy. The association between higher educational levels, knowledge of disease prevention, and vaccine acceptance or hesitancy has been widely investigated [16,94,95,96]. Individuals with higher educational levels and healthcare-related jobs might have adequate information on the global pandemic and consider vaccination to be a great step toward ending the pandemic, which can explain why this group had a lower risk of vaccine hesitancy. Our current findings are supported by previous studies in the context of dengue, Ebola, and monkeypox vaccines. Those studies also showed that knowledge of disease prevention and good health practices had a significant impact on the acceptance of vaccine candidates [97,98,99,100,101].Although we could not elucidate the role of socioeconomic status in COVID-19 vaccination hesitancy in this study, we found that some factors related to socioeconomic status, such as unemployment and household size (≥5 individuals), were associated with COVID-19 vaccination hesitancy. Socioeconomic status has been proven to affect health-related behavior [102]. Individuals with a low socioeconomic status might lack knowledge of the pandemic and the role of vaccination in the pandemic. Moreover, individuals with a low socioeconomic status might also lack social interaction; therefore, they might lack adequate knowledge concerning disease prevention, which could contribute to COVID-19 vaccination hesitancy. Previous meta-analyses in this context did not assess the role of socioeconomic status in COVID-19 vaccination hesitancy. However, in other settings, such as in the case of dengue vaccines, socioeconomic status was found to affect vaccination acceptance [100].To the best of our knowledge, this meta-analysis is the first comprehensive study to assess COVID-19 vaccination hesitancy worldwide. In sub-group analysis, our study identified similar prevalence rates of hesitancy to COVID-19 vaccination in the general population, healthcare workers, and students; suggesting that interventions to reduce the risk of COVID-19 vaccination hesitancy in those populations do not need to be differentiated. In addition to reporting the global prevalence, we also identified the potential factors associated with hesitancy to receive COVID-19 vaccination. Although the COVID-19 vaccination program targets the global population, some people have been hesitant to receive the vaccine. Our study identified the factors associated with such hesitancy, thereby shedding light on the populations that require special attention in order for the vaccination program to be successful. We recommend customized interventions and education for these special populations. A study suggested that customized effective, ethical, and evidence-based communication may be able to increase the acceptance of the COVID-19 vaccination [103]. This customized intervention was suggested to provide by community leaders and healthcare practitioners to establish the trust of COVID-19 vaccination [88]. Moreover, a recent study also reported that providing the population with reliable information regarding the COVID-19 pandemic and the COVID-19 vaccination was associated with the increased rate of vaccination acceptance among the Israeli parents [104]. On the other hand, while we have provided the valuable information on the factors associated with the risk COVID-19 vaccine hesitancy, it should be realized that the main factor driving individuals to be able to receive the vaccinations is the proven effectiveness and safety of vaccines in well-documented long-term studies. However, among those exhibiting COVID-19 vaccination hesitancy, there are people who outright refuse vaccination. Therefore, further studies should be performed with a focus on this group.There are some potential limitations of our study. First, a meta-analysis is a methodological approach conducted by calculating the crude effect of the related factors to determine the evidence. However, the impact of potential confounding factors is difficult to evaluate. In the current study, potential confounding factors such as the types of COVID-19 vaccine, government regulations, source of information regarding COVID-19 vaccination, and environmental factors were not included; therefore, our findings should be interpreted carefully. We reported that considering the COVID-19 vaccine to be unsafe was one of the factors associated with increased risk of COVID-19 vaccination hesitancy. Considering that the different types of COVID-19 vaccine have different side effects; the factors of the type of vaccine might also govern the final findings. Moreover, the government regulations in several countries have implemented COVID-19 vaccination as a condition of administration, and the regulations in each country may have differences; thereby, this circumstance may also affect the final findings of this study. Therefore, we reiterate the importance of the basic tenet in studying the phenomenon of vaccine hesitancy, which is the time, context, place, and type specificity. All these peculiarities need to be considered in the efforts aiming to fathom the determinants of vaccine hesitancy [105]. Second, our study involved a multi-national population, and the knowledge of disease prevention among people with similar socioeconomic status and educational level might vary in each region. Third, all the papers included in our study had an observational research design. Therefore, further studies including randomized controlled trials are required in order to obtain better levels of evidence.
5. Conclusions
Our study estimated the global prevalence of COVID-19 vaccination hesitancy at 25%. It also recommended special interventions to minimize COVID-19 vaccination hesitancy among unmarried individuals, women, people with low educational levels, the unemployed, people living in households with five or more individuals, and those who believe COVID-19 vaccines to be unsafe.
Authors: Kimberly A Fisher; Sarah J Bloomstone; Jeremy Walder; Sybil Crawford; Hassan Fouayzi; Kathleen M Mazor Journal: Ann Intern Med Date: 2020-09-04 Impact factor: 25.391
Authors: Malik Sallam; Deema Dababseh; Huda Eid; Hanan Hasan; Duaa Taim; Kholoud Al-Mahzoum; Ayat Al-Haidar; Alaa Yaseen; Nidaa A Ababneh; Areej Assaf; Faris G Bakri; Suzan Matar; Azmi Mahafzah Journal: Int J Environ Res Public Health Date: 2021-03-01 Impact factor: 3.390
Authors: Ramy Mohamed Ghazy; Marwa Shawky Abdou; Salah Awaidy; Malik Sallam; Iffat Elbarazi; Naglaa Youssef; Osman Abubakar Fiidow; Slimane Mehdad; Mohamed Fakhry Hussein; Mohammed Fathelrahman Adam; Fatimah Saed Alabd Abdullah; Wafa Kammoun Rebai; Etwal Bou Raad; Mai Hussein; Shehata F Shehata; Ismail Ibrahim Ismail; Arslan Ahmed Salam; Dalia Samhouri Journal: Int J Environ Res Public Health Date: 2022-09-25 Impact factor: 4.614